Elevated plasma glycocalicin levels and decreased ristocetin-induced platelet agglutination in hemodialysis patients

American Journal of Kidney Diseases

Volumn 32, Issue 1, 1998, Pages 132-138

  Himmelfarb, Jonathan ^a   Nelson, Stephen ^b   McMonagle, Ellen ^b   Holbrook, Diane ^b   Benoit, Stephen E ^b   Michelson, Alan D ^b   Ault, Kenneth ^a  

^a MAINE MEDICAL CENTER   (United States)

^b NONE

Author keywords

Glycocalicin; Glycoprotein; Hemodialysis; Platelet; Ristocetin

Indexed keywords

GLYCOCALICIN; GLYCOPROTEIN IB; RISTOCETIN;

ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; PERITONEAL DIALYSIS; THROMBOCYTE AGGLUTINATION; UREMIA; VASCULAR ENDOTHELIUM;

EID: 0031807965     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.1998.v32.pm9669434     Document Type: Article

References (56)

1. Reisman D: Hemorrhages in the course of Bright's disease with special reference to the occurrence of hemorrhagic diathesis of nephritic origin. Am J Med Sci 134:709-716, 1907
2. Steiner RW, Coggins C, Carvalho ACA: Bleeding in uremia: A useful test to assess clinical bleeding. Am J Hematol 7:107-117, 1979
3. Jaiyesimi AE, Mba EC, Edeki IO: Usefulness of the bleeding time to predict the risk of clinical bleeding in patients with uraemia. Centr Afr J Med 36:132-135, 1990
4. Roth GJ: Review: Platelets and blood vessels: The adhesion event. Immunol Today 13:100-105, 1992
5. Castillo R, Lozano T, Escolar G, Revert L, Lopez J, Ordinas A: Defective platelet adhesion on vessel subendothelium in uremic patients. Blood 68:337-342, 1986
6. Escolar G, Cases A, Bastida E, Garrido M, Lopez J, Revert L, Castillo R, Ordinas A: Uremic platelets have a functional defect affecting the interaction of von Willebrand factor with glycoprotein IIb-IIIa. Blood 76:1336-1340, 1990
7. Zwaginga JJ, Ijsseldijk JW, Beeser-Visser N, de Groot PG, Vos J, Sixma JJ: High von Willebrand factor concentration compensates a relative adhesion defect in uremic blood. Blood 75:1498-1508, 1990
8. Clemetson KJ: Glycoproteins of the platelet plasma membrane, in George JN, Nurden AT, Phillips DR (eds): Platelet Membrane Glycoproteins. New York, NY, Plenum, 1985, pp 51-85
9. Hickey MJ, Williams SA, Roth GJ: Human platelet GPIX: An adhesive prototype of leucine-rich glycoproteins with flank-center-flank structures. Proc Natl Acad Sci USA 86:6773-6777, 1989
10. Adelman B, Michelson AD, Greenberg J, Handin RI: Proteolysis of platelet glycoprotein Ib by plasmin is facilitated by plasmin lysine-binding regions. Blood 68:1280-1284, 1986
11. Michelson AD, Barnard MR: Plasmin-induced redistribution of platelet glycoprotein Ib. Blood 76:2005-2010, 1990
12. Loscalzo J, Handin RJ: Platelet glycocalicin. Methods Enzymol 215:289-293, 1992
13. Coller BS, Kalomiris E, Steinberg M, Schudder LE: Evidence that glycocalicin circulates in normal plasma. J Clin Invest 73:794-799, 1984
14. Steinberg MH, Kelton JG, Coller BS: Plasma glycocalicin: An aid in the classification of thrombocytopenic disorders. N Engl J Med 317:1037-1042, 1987
15. Beer JH, Buchi L, Steiner B: Glycocalicin: A new assay - The normal plasma levels and its potential usefulness in selected diseases. Blood 83:691-702, 1994
16. Michelson AD, Loscalzo J, Melnick B, Coller BS, Handin RI: Partial characterization of a binding site for von Willebrand factor on glycocalicin. Blood 67:19-26, 1986
17. Jandrot-Perrus M, Clemetson KJ, Huisse MG, Guillin MC: Thrombin interaction with platelet glycoprotein Ib: Effect of glycocalicin on thrombin specificity. Blood 80:2781 2786, 1992
18. Himmelfarb J, Holbrook D, McMonagle E, Ault K: Increased reticulated platelets in dialysis patients. Kidney Int 51:834-839, 1997
19. Kestin AS, Valeri CR, Khuri SF, Loscalzo J, Ellis PA, MacGregor H, Birjiniuk V, Ouimet H, Pasche B, Nelson MJ, Benoit SE, Rodino LS, Barnard MR, Michelson AD: The platelet function defect of cardiopulmonary bypass. Blood 82:107-117, 1993
20. Roth GJ: Developing relationships: Arterial platelet adhesion, glycoprotein Ib, and leucine-rich glycoproteins. Blood 77:5-19, 1991
21. Meyer D, Girma JP: von Willebrand factor: Structure and function. Thromb Haemost 70:99-104, 1993
22. Lopez JA: The platelet glycoprotein Ib-IX complex. Blood Coagul Fibrinol 5:97-119, 1994
23. Sakariassen KS, Ottenhof-Rovers M, Sixma JJ: Factor VIII-von Willebrand factor requires calcium for facilitation of platelet adherence. Blood 63:996-1003, 1984
24. Kroll MH, Harris TS, Moake JL, Handin RI, Schafer AI: von Willebrand factor binding to platelet Gplb initiates signals for platelet activation. J Clin Invest 88:1568-1573, 1991
25. Weiss HJ, Turitto VT, Baumgartner HR: Platelet adhesion and thrombus formation on subendothelium in platelets deficient in glycoproteins IIb-IIIa, Ib, and storage granules. Blood 67:322-330, 1986
26. Miller JL, Hustad KO, Kupinski JM, Lyle VA, Kunicki TJ: Increased platelet sensitivity to ristocetin is predicted by the binding characteristics of a GPIb/IX determinant. Br J Haematol 74:313-319, 1990
27. Sloand EM, Sloand JA, Prodouz K, Klein HG, Yu MW, Harvath L, Fricke W: Reduction of platelet glycoprotein Ib in uraemia. Br J Haematol 77:375-381, 1991
28. Benigni A, Boccardo P, Galbusera M, Monteagudo J, De Marco L, Remuzzi G, Ruggeri ZM: Reversible activation defect of the platelet glycoprotein IIb-IIIa complex in patients with uremia. Am J Kidney Dis 22:668-676, 1993
29. Nomura S, Hamamoto K, Kawakatsu T, Kido H, Yamaguchi K, Fukuroi T, Suzuki M, Yanabu M, Shouzu A, Nishikawa M, Kikawa T, Fukuhara S: Analysis of platelet abnormalities in uremia with and without Glanzmann's thrombasthenia. Nephron 68:442-448, 1994
30. Yoshida E, Fujimura Y, Ikeda Y, Takeda I, Yamamoto Y, Nishikawa K, Miyataka K, Oonuki M, Kawasaki T, Katayama M, Narita N: Impaired high shear stress-stress-induced platelet aggregation in patients with chronic renal failure undergoing haemodialysis. Br J Haematol 89:861-867, 1995
31. Liani M, Salvati F, Tresca E, Di Paolo G, Vitacolonna L, Golato M, Velussi C: Arteriovenous fistula obstruction and expression of platelet receptors for von Willebrand factor and for fibrinogen (glycoproteins GpIb and GpIIb/ IIIa) in hemodialysis patients. Int J Artif Organs 19:451-454, 1996
32. Tassies D, Reverter JC, Cases A, Escolar G, Villamor N, Lopez-Pedret J, Castillo R, Ordinas A: Reticulated platelets in uremic patients: Effect of hemodialysis and continuous ambulatory peritoneal dialysis. Am J Hematol 50:161-166, 1995
33. Sreedhara R, Itagaki I, Hakim RM: Uremic patients have decreased shear-induced platelet aggregation mediated by decreased availability of glycoprotein IIb-IIIa receptors. Am J Kidney Dis 27:355-364, 1996
34. Sloand JA, Sloand EM: Studies on platelet membrane glycoproteins and platelet function during hemodialysis. J Am Soc Nephrol 8:799-803, 1997
35. Komarnicki M, Kazmierczak M, de Mezer-Dambek M: Binding of monoclonal antibodies to platelet glycoproteins Ib and IIb/IIIa in uremic patients. Nephron 75:283-285, 1997
36. Sreedhara R, Itagaki I, Lynn B, Hakim RM: Defective platelet aggregation in uremia is transiently worsened by hemodialysis. Am J Kidney Dis 25:555-563, 1995
37. Gralnick HR, McKeown LP, Williams SB, Shafer BC: Plasma and platelet von Willebrand factor defects in uremia. Am J Med 85:806-810, 1988
38. Kazatchkine M, Sultan Y, Caen JP, Bariety J: Bleeding in renal failure: A possible cause. BMJ 2:612-615, 1976
39. Willoughby MLN, Crouch SG: An investigation of the hemorrhagic tendency in renal failure. Br J Haematol 7:315-326, 1971
40. Remuzzi G, Livio M, Roncaglion MC, Mecca G, Donati MB, deGaetano G: Bleeding in renal failure: Is von Willebrand's factor implicated? BMJ 2:359-361, 1977
41. Janson PA, Jubelier SJ, Weinstein MJ, Deykin D: Treatment of the bleeding tendency in uremia with cryoprecipitate. N Engl J Med 303:1318-1322, 1980
42. Mannucci PM, Remuzzi G, Pusineri F, Lombardi R, Valsecchi C, Mecca G, Zimmerman TS: Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 308:8-12, 1983
43. Stewart JH, Castaldi PA: Uremic bleeding: A reversible platelet defect corrected by dialysis. Q J Med 36:409-423, 1967
44. Starzl TE: Blood coagulation in uremia before and after hemodialysis and transplantation of the kidney. Arch Surg 92:184-191, 1966
45. Benigni A, Livo M, Dodesini P, Schieppati A, Panigada M, Mecca G, de-Gartano G, Remuzzi G: Inhibition of human platelet aggregation by parathyroid hormone. Is cyclic AMP implicated? Am J Nephrol 5:243-247, 1985
46. Mannhalter CH, Deutsch E, Kopsa E: Clotting activities and antigen concentrations of contact factors in kidney disease. Thromb Res 39:475-484, 1985
47. Vlacoyannis J, Schoeppe W: Adenylate cyclase activity and cyclic AMP content of human platelet in uraemia. Eur J Clin Invest 12:379-381, 1982
48. Benigni A, Boccardo P, Galbusera M, Monteagudo J, De Marco L, Remuzzi G, Ruggeri ZM: Reversible activation defect of the platelet glycoprotein IIb-IIIa complex in patients with uremia. Am J Kidney Dis 22:668-676, 1993
49. Di Minno G, Martinez J, McKean M, De La Rosa J, Burke JF, Murphy S: Platelet dysfunction in uremia: Multifaceted defect partially corrected by dialysis. Am J Med 79:552-559, 1985
50. Remuzzi G, Cavenaghi AE, Mecca G, Donati MB: Prostacyclin-like activity and bleeding in renal failure. Lancet 2:1195-1197, 1977
51. Defreyn G, Vergara Dauden M, Machin S, Vermylen J: A plasma factor in uraemia which stimulates prostacyclin release from cultured endothelial cells. Thromb Res 19:695-699, 1980
52. Zoja C, Vigano G, Bergamelli A, Benigni A, deGaetano G, Remuzzi G: Prolonged bleeding time and increased vascular prostacyclin in rats with chronic renal failure: Effects of conjugated estrogens. J Lab Clin Med 112:380-386, 1988
53. Remuzzi G, Perico N, Zoja C, Corna D, Macconi D, Vigano G: Role of endothelium-derived nitric oxide in the bleeding tendency of uremia J Clin Invest 86:1768-1771, 1990
54. Moia M, Mannucci PM, Vizzotto L: Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin. Lancet 8570:1227-1229, 1987
55. Cases A, Escolar G, Reverter JC, Ordinas A, Lopez-Pedret J, Revert L, Castillo R: Recombinant human erythropoietin treatment improves platelet function in uremic patients. Kidney Int 42:668-672, 1992
56. Zwaginga JJ, Ijsseldijk MJW, de Groot PG, Kooistra M, Vos J, van Es A, Koomans HA, Struyvenberg A, Sixma JJ: Treatment of uremic anemia with recombinant erythropoietin also reduces the defects in platelet adhesion and aggregation caused by uremic plasma. Thromb Haemost 66:638-647, 1991